EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Preclinical safety assessments are absolutely vital in drug development. Before a new drug can be tested in humans, it must undergo rigorous evaluation to ensure its safety and efficacy. Preclinical ...

LILLE, France & PARIS--(BUSINESS WIRE)--Regulatory News: Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research ...

Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates. For Sana, that means halting work on a ...

The ABPI says that industry and academia must come together to bridge the gap between academic and commercially ready preclinical models.

TORONTO--(BUSINESS WIRE)--Conscience, a non-profit focused on accelerating drug discovery in areas of unmet medical need using open science and radical collaboration, is pleased to announce three ...

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...